Molecular mechanisms of pancreatic cancer and potential targets of treatment

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 3, 2007, Pages 279-296

  Aho, Ursula ^a   Zhao, Xia ^a   Löhr, Matthias ^b   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ACETYLCYSTEINE; BEVACIZUMAB; BORTEZOMIB; CANNABINOID; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; K RAS PROTEIN; MARIMASTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; PROTEIN P53; ROFECOXIB; SMAD4 PROTEIN; TANOMASTAT; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; WORTMANNIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; EXCISION REPAIR; GENE MUTATION; HUMAN; MISMATCH REPAIR; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOKINES; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MUTATION; NF-KAPPA B; PANCREATIC NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847216123     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520601106384     Document Type: Review

References (203)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer Statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. The National Board of Health and Welfare. Cancer incidence in Sweden. Health Dis 2004:66.
3. Freeman JW, DeArmond D, Lake M, Huang W, Venkatasubbarao K, Zhao S. Alterations of cell signaling pathways in pancreatic cancer. Front Biosci 2004;9:1889-98.
4. Cowgill SM, Muscarella P. The genetics of pancreatic cancer. Am J Surg 2003;186:279-86.
5. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56:5360-4.
6. Hruban RH, Petersen GM, Ha PK, Kern SE. Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 1998;7:1-23.
7. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. Jpn. J Clin Oncol 2004;34:238-44.
8. Lynch HT, Brand RE, Lynch JF, Fusaro RM, Kern SE. Hereditary factors in pancreatic cancer. J Hepatobiliary Pancreat Surg 2002;9:12-31.
9. Lynch HT, Frichot BC, Lynch P, Lynch J, Gurigis HA. Family studies of malignant melanoma and associated cancer. Surg Gynecol Obstet 1975;141:517-22.
10. Schenk M, Schwartz AG, O'Neal E, Kinnard M, Greenson JK, Fryzek JP, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst 2001;93:640-4.
11. Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000;11:915-23.
12. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
13. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
14. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
15. Andersson R, Dervenis C, Haraldsen P, Leveau P. Nutritional aspects in the management of pancreatic cancer. Ann Gastroenterol 2001;13:221-4.
16. Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 1995;181:483-503.
17. Löhr M. Is it possible to survive pancreatic cancer? Nat Clin Pract Gastroenterol Hepatol 2006;3:236-7.
18. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature Reviews Cancer 2002;2:897-909.
19. Farrow B, Sugiyama Y, Chen A, Uffort E, Nealon W, Mark Evers B. Inflammatory mechanisms contributing to pancreatic cancer development. Ann Surg 2004;239:763-9; discussion 769-71.
20. Blanchard JA, II, Barve S, Joshi-Barve S, Talwalker R, Gates LK, Jr. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci 2000;45:927-32.
21. Friess H, Yamanaka Y, Büchler M, Berger HG, Kobrin MS, Baldwin RL, et al. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993;53:2704-7.
22. Friess H, Yamanaka Y, Büchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993;105:1846-56.
23. Garcea G, Dennison AR, Steward WP, Berry DP. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005;5:514-29.
24. Luo J, Guo P, Matsuda K, Truong N, Lee A, Chun C, et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001;92:361-9.
25. Saito K, Ishikura H, Kishimoto T, Kawarada Y, Yano T, Takahashi T, et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int J Cancer 1998;75:284-9.
26. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Büchler MW, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999;18:5363-72.
27. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;5:3711-21.
28. Shi Q, Le X, Abbruzzese JL, Peng Z, Qian C-N, Tang H, et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001;61:4143-54.
29. Watanabe N, Tsuji N, Kobayashi D, Yamauchi N, Akiyama S, Sasaki H, et al. Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity in pancreatic carcinoma cells via enhancement of the heart shock element-binding activity of heart shock factor 1. Chemotherapy 1997;43:406-14.
30. Yamanaka Y, Friess H, Buchler M, Beger HG, Uchida E, Onda M, et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53:5289-96.
31. Löhr M, Schmidt C, Ringel J, Kluth M, Müller P, Nizze H, et al. Transforming growth factor beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 2001;61:550-5.
32. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004;10:789-99.
33. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
34. Furukawa T, Sunamura M, Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 2006;97:1-7.
35. Löhr M, Klöppel G, Maisonneuve P, Lowenfels AB, Lüttges J. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia 2005;7:17-23.
36. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4.
37. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.
38. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9.
39. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20:1218-49.
40. Hotz HG, Hines OJ, Foitzik T, Reber HA. Animal models of exocrine pancreatic cancer. Int J Colorectal Dis 2000;15:136-43.
41. de Vos tot Nederveen Cappel WH, Offerhaus GJA, van Puijenbroek M, Caspers E, Gruis NA, de Snoo FA, et al. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-Leiden). Clin Cancer Res 2003;9:3598-605.
42. Fenwick C, Na S-Y, Voll RE, Zhong H, Im S-Y, Lee JW, et al. A subclass of ras proteins that regulate the degradation of IB. Science 2000;287:869-73.
43. Mayo MW, Wang C-Y, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, et al. Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic ras. Science 1997;278:1812-5.
44. Lüttges J, Diederichs A, Menke MAOH, Vogel I, Kremer B, Klöppel G. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000;88:2495-504.
45. Löhr M, Müller P, Mora J, Brinkmann B, Ostwald C, Farré A, et al. p53 and K-ras mutations in pancreatic juice samples from patients with chronic pancreatitis. Gastrointest Endosc 2001;53:734-43.
46. Lüttges J, Reinecke-Lüthge A, Mollmann B, Menke MA, Clemens A, Klimpfinger M, et al. Duct changes and K-ras mutations in the disease-free pancreas: analysis of type, age relation and spatial distribution. Virchows Arch 1999;435:461-8.
47. Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochimica et Biophysica Acta (BBA) - Rev Cancer 2005;1756:97-101.
48. Skuse GR, Ludlow JW. Tumour suppressor genes in disease and therapy. Lancet 1995;345:902-6.
49. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
50. Lüttges J, Galehdari H, Brocker V, Schwarte-Waldhoff I, Henne-Bruns D, Kloppel G, et al. Allelic loss is often the first hit in the biallelic inactivation of the p53 and dpc4 genes during pancreatic carcinogenesis. Am J Pathol 2001;158:1677-83.
51. Maurice D, Pierreux CE, Howell M, Wilentz RE, Owen MJ, Hill CS. Loss of Smad4 function in pancreatic tumors. C-terminal trunctuation leds to decreased stability. J Biol Chem 2001;276:43175-81.
52. Moore PS, Beghelli S, Zamboni G, Scarpa A. Genetic abnormalities in pancreatic cancer. Mol Cancer 2003;2:7.
53. Schutte M. DPC4/SMAD4 Gene alterations in human cancer, and their functional implications. Ann Oncol 1999;10:56-9.
54. Schutte M, Hruban RH, Geradts J, Maynard R, Hilgers W, Rabindran SK, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30.
55. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000;156:1821-5.
56. Biankin AV, Biankin SA, Kench JG, Morey AL, Lee CS, Head DR, et al. Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002;50:861-8.
57. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
58. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32.
59. Hata A, Shi Y, Massague J. TGF-beta signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 1998;4:257-62.
60. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 2000;103: 295-309.
61. Friess H, Kleeff J, Korc M, Büchler MW. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 1999;16:281-90.
62. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000;26:29-52.
63. Hahn SA, Hoque AT, Moskaluk CA, da Costa LT, Schutte M, Rozenblum E, et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 1996;56:490-4.
64. Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003;22:6857-64.
65. Wilentz RE, Iacobuzio-Donahue CA, Argani P, McCarthy DM, Parsons JL, Yeo CJ, et al. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6.
66. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Buchler M, et al. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. Cancer Lett 1993;69:151-60.
67. Redston MS, Caldas C, Seymour AB, Hruban RH, da Costa L, Yeo CJ, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33.
68. Ruggeri B, Zhang SY, Caamano J, DiRado M, Flynn SD, Klein-Szanto AJ. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-11.
69. Macdonald JS, McCoy S, Whitehead RP, Iqbal S, Wade JL, Giguere JK, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005;23:485-7.
70. Venkatasubbarao K, Choudary A, Freeman JW. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 2005;65:2861-71.
71. McKenna S, Eatock M. The medical management of pancreatic cancer: A review. Oncologist 2003;8:149-60.
72. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, et al. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 2003;22:7781-95.
73. Greten FR, Weber CK, Greten TF, Schneider G, Wagner M, Adler G, et al. Stat3 and NF-[kappa]B activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 2002;123:2052-63.
74. Brunner TB, Hahn SM, McKenna WG, Bernhard EJ. Radiation sensitization by inhibition of activated ras. Strahlentherapie Onkol 2004;180:731-40.
75. Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2003;21:1301-6.
76. Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
77. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, et al. K- and N-Ras Are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-64.
78. Andrén-Sandberg Å. Pancreatic tumors. State of the art in 2005: aiming at evidence-based medicine and surgery. http://ebooks.pancreasweb. com/Title-Pub-ViewBookDesc.asp?EbookId=7, April 5, 2006.
79. Balaz P, Friess H, Buchler MW. Growth factors in pancreatic health and disease. Pancreatology 2001;1:343-55.
80. Boonstra J, Rijken P, Humbel B, Cremers F, Verkleij A, en Henegouwen PvB. The epidermal growth factor. Cell Biol Int 1995;19:413-30.
81. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW. Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 2001;21:27-44.
82. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999;11:184-9.
83. Matsuda K, Idezawa T, You XJ, Kothari NH, Fan H, Korc M. Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002;62:5611-7.
84. Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Related Cancer 2001;8:11-31.
85. Riese Ii DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 1998;20:41-8.
86. Yamada M, Ikeuchi T, Hatanaka H. The neurotrophic action and signalling of epidermal growth factor. Prog Neurobiol 1997;51:19-37.
87. Korc M, Finman JE. Attenuated processing of epidermal growth factor in the face of marked degradation of transforming growth factor-alpha. J Biol Chem 1989;264:14990-9.
88. Liu N, Furukawa T, Kobari M, Tsao M-S. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 1998;153:263-9.
89. Korc M, Meltzer P, Trent J. Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci USA 1986;83:5141-4.
90. Smith JJ, Derynck R, Korc M. Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci USA 1987;84:7567-70.
91. Shirk AJ, Kuver R. Epidermal growth factor mediates detachment from and invasion through collagen I and Matrigel in Capan-1 pancreatic cancer cells. BMC Gastroenterol 2005;5:12.
92. Greten FR, Wagner M, Weber CK, Zechner U, Adler G, Schmid RM. TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 2001;1:363-8.
93. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998;7:25-41.
94. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992;90:1352-60.
95. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
96. Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, et al. Randomized phase II - study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer - PARC: study protocol (ISRCTN56652283). BMC Cancer 2005;5:131.
97. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27.
98. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-66.
99. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6.
100. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
101. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) [meeting abstracts]. J Clin Oncol 2005;23:1.
102. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005;128:1606-25.
103. Xie K, Wei D, Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 2006;17:147-56.
104. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-43.
105. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci 1999;4:D141-52.
106. Korc M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2003;2:8.
107. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, Rockwell P, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998;17:155-61.
108. Büchler P, Reber HA, Ullrich A, Shiroiki M, Roth M, Büchler MW, et al. Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003;134:772-82.
109. Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Buchler MW, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997;3:1309-16.
110. Tang RF, Wang SX, Peng L, Wang SX, Zhang M, Li ZF, et al. Expression of vascular endothelial growth factors A and C in human pancreatic cancer. World J Gastroenterol 2006;12:280-6.
111. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999;79:1553-63.
112. Knoll MR, Rudnitzki D, Sturm J, Manegold BC, Post S, Jaeger TM. Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology 2001;48:1162-5.
113. Niedergethmann M, Hildenbrand R, Wolf G, Verbeke CS, Richter A, Post S. Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection. Int J Pancreatol 2000;28:31-9.
114. Niedergethmann M, Hildenbrand R, Wostbrock B, Hartel M, Sturm JW, Richter A, et al. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002;25:122-9.
115. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-45.
116. Hotz HG, Reber HA, Hotz B, Sanghavi PC, Yu T, Foitzik T, et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001;5:131-8.
117. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O. Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 2003;27:405-11.
118. Solorzano CC, Baker CH, Bruns CJ, Killion JJ, Ellis LM, Wood J, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2001;16:359-70.
119. Hotz HG, Gill PS, Masood R, Hotz B, Buhr HJ, Foitzik T, et al. Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg 2002;6:159-66.
120. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, et al. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002;25:111-21.
121. Ogawa T, Takayama K, Takakura N, Kitano S, Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002;9:633-40.
122. Saif MW. Anti-angiogenesis therapy in pancreatic carcinoma. J Pathol 2006;7:163-73.
123. Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
124. Hochster H, Haller D, de Gramont A, Berlin J, Philip P, Moore M, et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676-85.
125. Cancer and Leukemia Group B. http://www.calgb.org/index.php?action= fullnews&id=28, September 28. 2006.
126. Chu J, Lloyd FL, Trifan OC, Knapp B, Rizzo MT. Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer. Mol Cancer Ther 2003;2:1-7.
127. Ding XZ, Tong WG, Adrian TE. Blockade of cyclooxygenase-2 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Anticancer Res 2000;20:A2625.
128. Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, Reber HA, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003;306:887-97.
129. Wei D, Wang L, He Y, Xiong HQ, Abbruzzese JL, Xie K. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer Res 2004;64:2030-8.
130. Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova ML, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004;64:5617-23.
131. Vane JR, Bakhle YS, Botting RM. Cycloooxygenases 1 and 2. Annual review of pharmacology and toxicology 1998;38:97-120.
132. Needleman P, Truk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Annu Rev Biochem 1986;55:69-102.
133. Smith WL, Marnett LJ, DeWitt DL. Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 1991;49:153-79.
134. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
135. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. Cancer 2001;91:333-8.
136. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, et al. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol 2002;17:914-21.
137. Merati K, Said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, et al. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001;24:447-52.
138. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
139. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res 1999;5:2018-24.
140. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 1999;59:987-90.
141. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
142. Albazaz R, Verbeke CS, Rahman SH, McMahon MJ. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 2005;5:361-9.
143. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006;59:382-6.
144. Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, et al. Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res 2005;65:982-90.
145. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609-14.
146. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
147. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc-delta-716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
148. Zhu J, Huang J-W, Tseng P-H, Yang Y-T, Fowble J, Shiau C-W, et al. From the Cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.
149. Okami J, Nakamori S, Hiraoka N, Tsujie M, Hayashi N, Yamamoto H, et al. Suppression of pancreatic cancer cell invasion by a cyclooxygenase-2-specific inhibitor. Clin Exp Metastasis 2003;20:577-84.
150. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
151. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
152. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
153. Khanna D, Khanna PP, Furst DE. COX-2 controversy: where are we and where do we go from here? Inflammopharmacology 2005;13:395-402.
154. Ostor AJ, Hazleman BL. The murky waters of the coxibs: a review of the current state of play. Inflammopharmacology 2005;13:371-80.
155. Rainsford KD. Introduction: the coxib controversies. Inflammopharmacology 2005;13:331-41.
156. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005;4:1943-51.
157. Yip-Schneider MT, Sweeney CJ, Jung S-H, Crowell PL, Marshall MS. Cell cycle effects of nonsteroidal antiinflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma Cells. J Pharmacol Exp Ther 2001;298:976-85.
158. Tseng WW, Deganutti A, Chen MN, Saxton RE, Liu CD. Selective cyclooxygenase-2 inhibitor rofecoxib (Vioxx) induces expression of cell cycle arrest genes and slows tumor growth in human pancreatic cancer. J Gastrointest Surg 2002;6:838-43;discussion 844.
159. Trifan OC, Smith RM, Thompson BD, Hla T. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin- independent mechanism. J Biol Chem 1999;274:34141-7.
160. Eibl G, Reber HA, Wente MN, Hines OJ. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003;26:A33.
161. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004;3:1421-6.
162. El-Rayes BF, Zalupski MM, Shields AF, Ferris AM, Vaishampayan U, Heilbrun LK, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 2005;23:583-90.
163. Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial. Cancer Chemother Pharmacol 2006;57:185-90.
164. Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL. A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 2005;55:559-64.
165. Milella M, Gelibter A, Di Cosimo S, Enzo E, Ruggeri M, Carlini P, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-8.
166. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 2004;279:16452-62.
167. Baldwin AS. The NF-kappaB and IkappaB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-81.
168. Adams J. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 2002;6:493-500.
169. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappaB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
170. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, et al. Function of nuclear factor kappa-B in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
171. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-7.
172. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-22.
173. Alberts SR, Foster NR, Morton RF, Kugler J, Schaefer P, Wiesenfeld M, et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann Oncol 2005;16:1654-61.
174. Perugini RA, McDade TP, Vittimberga JFJ, Callery MP. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 2000;90:39-44.
175. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genets Devel 1998;8:55-62.
176. Burgering BMT, Coffer PJ. Protein kinase B (c-Akt) in
177. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998;10:262-7.
178. Franke TF, Yang S-I, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36.
179. Ng SSW, Tsao M-S, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000;60:5451-5.
180. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 2001;70:535-602.
181. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 2002;1:989-97.
182. Le X, Shi Q, Wang B, Xiong Q, Qian C, Peng Z, et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000;20:935-46.
183. Sawai H, Funahashi H, Okada Y, Matsuo Y, Sakamoto M, Yamamoto M, et al. Interleukin-1alpha enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Med Sci Monit 2005;11:BR343-50.
184. Kusano C, Takao S, Noma H, Yoh H, Aikou T, Okumura H, et al. N-acetyl cysteine inhibits cell cycle progression in pancreatic carcinoma cells. Hum Cell 2000;13:213-20.
185. Grau AM, Zhang L, Wang W, Ruan S, Evans DB, Abbruzzese JL, et al. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 1997;57:3929-34.
186. Kleeff J, Maruyama H, Friess H, Büchler MW, Falb D, Korc M. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Comm 1999;255:268-73.
187. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis [review]. Int J Oncol 1998;13:893-906.
188. Aoyagi Y, Oda T, Kinoshita T, Nakahashi C, Hasebe T, Ohkohchi N, et al. Overexpression of TGF-beta by infiltrated granulocytes correlates with the expression of collagen mRNA in pancreatic cancer. Br J Cancer 2004;91:1316-26.
189. 2 receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997;42:2054-63.
190. Jesnowski R, Furst D, Ringel J, Chen Y, Schrodel A, Kleeff J, et al. Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. Lab Invest 2005;85:1276-91.
191. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001;19:3447-55.
192. Koshiba T, Hosotani R, Wada M, Miyamoto Y, Fujimoto K, Lee J-U, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 1998;82:642-50.
193. Yang GY, Wagner TD, Fuss M, Thomas CR, Jr. Multimodality approaches for pancreatic cancer. CA Cancer J Clin 2005;55:352-67.
194. Brown P. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat 1998;52:125-36.
195. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92.
196. Haq M, Shaeii AE, Zervos EE, Rosemurgy AS. In vitro and in vivo matrix metalloproteinase production by pancreatic cancer cells and by distant organs. Int J Surg Invest 2000;1:459-65.
197. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005;41:2213-36.
198. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.
199. Yoshida Y, Tasaki K, Miyauchi M, Narita M, Takenaga K, Yamamoto H, et al. Impaired tumorigenicity of human pancreatic cancer cells retrovirally transduced with interleukin-12 or interleukin-15 gene. Cancer Gene Ther 2000;7:324-31.
200. Sangro B, Mazzolini G, Ruiz J, Herraiz M, Quiroga J, Herrero I, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97.
201. Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004;95:283-9.
202. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
203. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 2001;92:441-50.